Evidence map›Paper›PMID 40060891›Full record

ArticleiScience2025

Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts.

Haokang Feng, Zhixue Chen, Jianang Li, Jiale Feng, Fei Yang, Fansheng Meng, Hanlin Yin, Yuquan Guo, Huaxiang Xu, Yuxin Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Haokang FengDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhixue ChenDepartment of Gastroenterology and Hepatology, Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jianang LiDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiale FengDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Fei YangInnovative Institute of Tumor Immunity and Medicine (ITIM), Hefei, Anhui, China.
Fansheng MengLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Hanlin YinDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yuquan GuoDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Huaxiang XuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yuxin LiuDepartment of Basic Medicine and Institute of Liver Diseases, Shan Xi Medical University, Taiyuan 030000, China.
Runjie LiuDepartment of Basic Medicine and Institute of Liver Diseases, Shan Xi Medical University, Taiyuan 030000, China.
Wenhui LouDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Liang LiuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xu HanDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Hua SuInstitutes of Biomedical Sciences, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Lei ZhangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC), characterized by the absence of effective biomarkers and therapies, remains highly fatal. Data regarding the correlations between PC risk and individual plasma proteome known for minimally invasive biomarkers are scarce. Here, we analyzed 1,345 human plasma proteins using proteome-wide association studies, identifying 78 proteins significantly associated with PC risk. Of these, four proteins (ROR1, FN1, APOA5, and ABO) showed the most substantial causal link to PC, confirmed through Mendelian randomization and colocalization analyses. Data from two clinical cohorts further demonstrated that FN1 and ABO were notably overexpressed in both blood and tumor samples from PC patients, compared to healthy controls or para-tumor tissues. Additionally, elevated FN1 and ABO levels correlated with shorter median survival in patients. Multiple drugs targeting FN1 or ROR1 are available or in clinical trials. These findings suggest that plasma protein FN1 associated with PC holds potential as both prognostic biomarkers and therapeutic targets.

Indexed as

Clinical findingHealth sciencesProteomics

Identifiers

PMID40060891
PMCPMC11889678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.